Answers are grounded in this paper and cite their sources.
Several new treatments for relapsing-remitting multiple sclerosis (RRMS) are currently being tested in phase III clinical trials. Fingolimod (FTY720) is an oral sphingosine 1 phosphate receptor (SP1PR) agonist inhibiting lymphocyte egress from lymph nodes.1,2 Fingolimod has shown efficacy in experimental autoimmune encephalitis3 and during phase II testing in RRMS.4 An orally available and well-tolerated drug would be a milestone in MS treatment. Known side effects are upper respiratory tract infections, dyspnea, bradycardia, diarrhea, nausea, and liver enzyme elevation. Severe adverse events included cases of facial herpes zoster,4 enterocolitis,4 macular edema,5 and posterior leukencephalopathy.4 ### Case report. We present a case of severe hemorrhagic focal encephalitis in a 28-year-old woman with mild RRMS during treatment with fingolimod in the FREEDOMS II trial. Within the previous 48 months, she had had three clinical episodes (paresthesias, optic neuritis) and only been treated with steroids. Seven T2-weighted lesions—one gadolinium (Gd) enhancing—were noticed at time of inclusion on cranial MRI (cMRI) and oligoclonal bands were positive. Visual acuity was 0.95 (20/21) (Expanded Disability Status Scale 2.0). She was recruited into the trial 7 months before admission and no disease activity had occurred since. On admission, she presented with a 1-day history of headache, nausea, and vomiting. Lumbar puncture revealed mild pleocytosis (29 cells/μL) and elevated CSF protein (571 mg/L). Neither acute-phase proteins (C-reactive protein and fibrinogen) nor leukocytes were elevated. …
No takes yet. Share an insight, caveat, or question.
Leypoldt et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: